The novel therapy luspatercept (Reblozyl, Bristol Myers Squibb) was more effective than epoetin alfa for achieving independence from red blood cell transfusions and for the duration of response in patients with low-risk but transfusion-dependent myelodysplastic syndromes (MDS) in a phase 3 trial.
Although the drug already has an indication for transfusion-dependent MDS patients who have failed to respond to erythropoietin-stimulating agents (ESAs), the new data “show that